Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial
Jean-Pascal H. Machiels, Tim Henrik Brümmendorf, Sylvie Zanetta-Devauges(Centre Georges François Leclerc), Christoph Tinchon(LKH Hochsteiermark), Paul Ruff, L. Svensson(Boehringer Ingelheim (Denmark)), Pol Specenier(Antwerp University Hospital), Sylvie Rottey(Ghent University Hospital), Enzo Maria Ruggeri, Thomas Bauernhofer, Luciano de Souza Viana(Hospital de Câncer de Barretos), M. Alfonsi(Centre Hospitalier Universitaire de Nantes), Ulrich Keilholz(German Cancer Research Center), Lena Specht(University of Copenhagen), Marco Benasso, E. Ehrnrooth(Boehringer Ingelheim (Germany)), Jordi Ginés Rubió, Isabelle Tennevet, Francesco Caponigro, José Getulio Martins Segalla(Hospital Amaral Carvalho), Joseph M del Campo(Vall d'Hebron Hospital Universitari), Jean‐Marc Tourani, Rita Axelrod(Thomas Jefferson University), Yungpo Bernard Su, Joël Guigay, LUX-H 1 investigators, Kunitoshi Yoshino, Gilberto de Castro, Toshinari Yagi, Makoto Tahara, Robert I. Haddad, Lisa F. Licitra, Miguel Angel Alvarez Avitia, Salam Billan, Shunji Takahashi, Xiuyu Julie Cong, Jose Manuel Trigo, Jérôme Fayette, Vladimir Vladimirov, Javier Martínez Trufero, Philippe Schafhausen, Tomoya Yokota(Target (United States)), Ezra E. W. Cohen, J. Stöhlmacher
RWTH Publications (RWTH Aachen)
January 1, 2015
Cited by 0
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Randomized Phase III Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Stage III to IV Head and Neck Carcinoma: RTOG 0522
|Journal of Clinical Oncology|2014|830
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial
|The Lancet|2008|644
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2019|621